

18 **Abstract**

19 **Background:** Previous studies reported recurrent SARS-CoV-2 RNA positivity in individuals
20 who had recovered from COVID-19 infections. However, little is known regarding the
21 systematic review of recurrent SARS-CoV-2 RNA positivity. The current study conducted a
22 systematic review and meta-analysis, aimed to estimate the incidence of recurrent SARS-CoV-2
23 RNA positivity after recovery from COVID-19 and to determine the factors associated with
24 recurrent positivity.

25 **Methods:** We searched the PubMed, MedRxiv, BioRxiv, the Cochrane Library,
26 ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry for
27 studies published to June 12, 2020. Studies were reviewed to determine the risk of bias. A
28 random-effects model was used to pool results. Heterogeneity was assessed using I^2 .

29 **Results:** Fourteen studies of 2,568 individuals were included. The incidence of recurrent SARS-
30 CoV-2 positivity was 14.81% (95% confidence interval [CI]: 11.44–18.19%). The pooled
31 estimate of the interval from disease onset to recurrence was 35.44 days (95% CI: 32.65–38.24
32 days), and from the last negative to recurrent positive result was 9.76 days (95% CI: 7.31–12.22
33 days). Patients with younger age (mean difference [MD]=-2.27, 95% CI: -2.95 to -1.80) and a
34 longer initial illness (MD=8.24 days; 95% CI: 7.54 – 8.95; $I^2=98.9%$) were more likely to
35 experience recurrent SARS-CoV-2 positivity, while patients with diabetes (RR=0.52; 95% CI:
36 0.30-0.90; $I^2=53%$), severe disease (RR=0.54; 95% CI: 0.35-0.84; $I^2=70%$), and a low
37 lymphocyte count (RR=0.58; 95% CI: 0.39 – 0.86; $I^2=48%$) were less likely to experience
38 recurrent SARS-CoV-2 positivity.

39 **Conclusions:** The incidence of recurrent SARS-CoV-2 positivity was 14.81%. The estimated
40 interval from disease onset to repeat positivity was 35.44 days, and the estimated interval from
41 the last negative result to recurrent positive result duration was 9.76 days.

42

43 **Key words:** COVID-19, SARS-CoV-2, recurrence, systematic review, meta-analysis, reverse
44 transcription polymerase chain reaction

45

46

47 **Background**

48 Globally, the reported number of confirmed infections and deaths due to the severe acute
49 respiratory syndrome coronavirus 2 (SARS-CoV-2 pandemic) was 7,410,510 and 418,294,
50 respectively, by June 12 2020.[1] Country governments have implemented public health
51 measures such as lockdowns, physical distancing, use of face masks, and frequent hand-washing;
52 however, the incidence of SARS-CoV-2 infection is still increasing. The proportion of severe
53 cases and case fatality rates have been reported to be 25.6% and 3.6%, respectively,[2] with
54 individuals with comorbidities being at greater risk of developing severe disease.[2,3]

55 The World Health Organization (WHO) has provided criteria for assessing the recovery
56 of patients hospitalized with coronavirus disease 2019 (COVID-19).[4] Recently, there have
57 been several reports of recurrent SARS-CoV-2 RNA positivity in individuals who had recovered
58 from COVID-19.[5,6] It was estimated that the incidence of recurrent SARS-CoV-2 positivity in
59 individuals who have recovered from COVID-19, ranged from 7.3%[5] to 21.4%.[6] However,
60 to date no systematic reviews have been published to provide a pooled estimate of the incidence
61 of recurrent positivity.. This systematic review aimed to: estimate the incidence of recurrent
62 SARS-CoV-2 positivity and determine the characteristics and risk factors related to the recurrent
63 SARS-CoV-2 positivity in patients who had recovered from COVID-19.

64

65 **Methods**

66 *Protocol and registration*

67 This review is written following the Preferred Reporting Items for Systematic Review,
68 and Meta-Analysis Protocol (PRISMA-P).[7] The protocol of this review was published in the

69 International Prospective Register of Systematic Reviews (PROSPERO) on May 14, 2020,
70 reference no. CRD42020186306.[8]

71

72 ***Search strategy and information resources***

73 A search was conducted on PubMed, MedRxiv, BioRxiv, Cochrane Library,
74 ClinicalTrials.gov, the WHO international register of clinical trials registry using the search term
75 in Medical Subjects Headings (MeSH) and free text: ("2019 nCoV" OR "2019nCoV" OR "2019
76 novel coronavirus" OR "COVID 19" OR "COVID19" OR "new coronavirus" OR "novel
77 coronavirus" OR "SARS CoV-2" OR (Wuhan AND coronavirus) OR "COVID 19" OR "SARS-
78 CoV" OR "2019-nCoV" OR "SARS-CoV-2") AND ((recurrence) OR (relapse) OR (re*infection)
79 OR (re*activation)).

80

81 ***Data management and study selection***

82 Literature search results were organized using Mendeley (Mendeley, Ltd, Elsevier, UK).
83 Article titles and abstracts retrieved from the databases were transferred to Mendeley citation
84 manager after being screened and checked for duplication. All records that did not meet the
85 eligibility criteria were excluded from the review.

86 The eligibility of articles based on their title and abstract was assessed independently by
87 MA and AF. If necessary, the full paper was retrieved to further determine the eligibility status.
88 In cases of disagreement regarding eligibility, consensus was reached by consulting a third
89 reviewer (MR). The eligibility criteria were: (i) the study designs are cross-sectional, case-
90 control or cohort design; (ii) the study reports the incidence of recurrent SARS-CoV-2 positivity

91 in individuals who had recovered from COVID-19 and its related factors; and (iii) the articles
92 included published or unpublished studies. The published studies may included both peer-
93 reviewed reports and pre-print reports. Studies in languages other than English were excluded if
94 no translated version of the manuscript was available.

95 The full text of the articles that met the eligibility for the review were then assessed. If
96 the data provided in the articles were incomplete, the author was contacted to obtain complete
97 data. Data collection forms were used for specific purposes, including the screening process,
98 determining eligibility, data collection, and incomplete data identification as well as the risk of
99 bias assessment.

100 ***Data extraction and quality assessment***

101 The following data items were extracted: authors, funding, study design, the population
102 of the study, number of episodes of recurrent SARS-CoV-2 positivity per case, and patient
103 characteristics. The patient characteristics considered included age, sex, body mass index,
104 clinical/laboratory manifestations, and comorbidities such as diabetes and hypertension. The
105 outcome was recurrent SARS-CoV-2 positivity in individuals who had recovered from COVID-
106 19, determined as based on positive result of reverse transcription polymerase chain reaction
107 (RT-PCR) on re-testing, after being followed-up or re-admitted after discharged from hospital.

108 We used the quality assessment tool for cross-sectional and cohort studies published by
109 the National Institutes of Health to assess the methodological quality of included studies.[9] Each
110 item was scored 0 or 1 point based on the criteria. A total of all items ranged from 0 to 14 was
111 used to assess the quality of the article. Based on the overall score, we categorized articles to
112 high risk of bias with score ≤ 6 , medium risk of bias with a score of 7–10, and low risk of bias

113 when the score was ≥ 11 . Each study was assessed for risk of bias independently by MA and MR.
114 Any disagreement in the risk of bias assessment was resolved by discussion to reach consensus
115 or by consulting UB and SA.

116 ***Data analysis***

117 We performed data analysis using Revman (Review Manager version 5.3.5 Copenhagen,
118 The Nordic Cochrane Centre, 2014). Random-effects meta-analysis was used to calculate the
119 pooled incidence of recurrent SARS-CoV-2 positivity with 95% confidence intervals. The
120 incidence for each individual study with its standard error (SE) adds to the study data in
121 RevMan. If the SE was not reported and the raw data could not be accessed, the SE was
122 calculated using the formula $SE = \sqrt{(p(1-p)/n)}$. Meta-analysis was used to calculate pooled
123 estimates of the time from disease onset to recurrent test positivity and the time from the last
124 negative test result to recurrent positivity.

125 Meta-analysis was also used to calculate the pooled relative risk (RR) of recurrent SARS-
126 CoV-2 positivity according to age, sex, hypertension, diabetes, other co-morbidities, disease
127 severity, body mass index (BMI), fever as the initial presenting complaint, days from onset to
128 negative conversion, lymphocyte count, D-dimer, and lung consolidation. We then assessed the
129 heterogeneity between studies using I^2 , with values of 25%, 50%, and 75% representing low,
130 moderate, and high heterogeneity, respectively.

131

132 **Results**

133 Our search on June 12, 2020, produced 397 records. Of these records, 392 were left after
134 the duplicates were removed. Of these records, 371 were excluded from the review because the

135 articles did not report recurrent SARS-CoV-2 positivity. Of this, 21 full texts were assessed for
136 eligibility and 14 studies were included in the meta-analysis (Figure 1).

137 Table 1 summarizes the characteristics of the finally selected studies. These studies were
138 published between Mar 17 and May 29, 2020. We included four non-peer-reviewed studies.
139 There was a total of 2,568 participants from all the studies combined, of which 318 experienced
140 recurrent SARS-CoV-2 positivity. Thirteen of the 14 studies were conducted in China and one
141 study was conducted in Brunei. Four of the Chinese studies were conducted in the city of Wuhan
142 and the rest were conducted in other cities. There were six studies (43%) with a cross-sectional
143 design, and four studies (29%) each with a retrospective cohort and prospective cohort design.
144 The most frequently used sample types were nasopharyngeal or oropharyngeal swabs alone
145 (46%), and the remaining studies used a variety of sample types including fecal, nasopharyngeal,
146 and oropharyngeal swabs. One study did not report the type of sample that was used.[10] The
147 median interval duration from disease onset to recurrence ranged from 21 to 50 days, while the
148 interval from the last negative to recurrent positive result ranged from 4 to 19 days. The risk of
149 bias was assessed as low in seven studies (50%), moderate in six studies (43%), and high in one
150 study (7%) (Supplementary Table 1).

151 The pooled estimate of the incidence of recurrent SARS-CoV-2 positivity was 14.81%
152 (95% CI: 11.44–18.19%) (Figure 2). Liu et al.[11] found the lowest incidence (7.33%, N=150),
153 and Li et al.[12] found the highest incidence (46.2%, N=13).

154 Seven studies provided results on the time from disease onset to recurrent positivity, and
155 eight studies provided results on the time from testing negative to recurrent positivity. The
156 pooled estimate of the interval from disease onset to recurrent positivity was 35.44 days (95%

157 CI: 32.65–38.24 days), and the pooled estimate of the last negative to recurrent positivity was
158 9.76 days (95% CI: 7.31–12.22 days) (Figures 3 and 4).

159 Patients with younger age were more likely to experience recurrent SARS-CoV-2
160 positivity (mean difference: -2.27 , 95% CI: -2.95 to -1.80), but there was considerable
161 heterogeneity between studies in the effect of age ($I^2=99\%$). Patients with diabetes were less
162 likely to experience recurrent SARS-CoV-2 positivity (RR: 0.52, 95% CI: 0.30-0.90, $I^2=53\%$).
163 Patients with severe COVID-19 were also less likely to experience recurrently positivity than
164 those with less severe disease (RR: 0.54, 95% CI: 0.35-0.84, $I^2=70\%$). A longer interval from
165 disease onset to the last negative PCR result during the first admission was associated with a
166 greater risk of recurrent SARS-CoV-2 positivity (mean difference: 8.24 days, 95% CI: 7.54–8.95
167 days, $I^2=98.9\%$). Patients with a low lymphocyte count ($<1.1 \times 10^9/L$) had a higher risk of
168 experiencing recurrent SARS-CoV-2 positivity (RR: 0.58, 95% CI: 0.39–0.86, $I^2=48\%$). We did
169 not find an association between sex, BMI, co-morbidity, hypertension, fever, lung consolidation,
170 or D-dimer and the risk of recurrent SARS-CoV-2 positivity (Figure 5).

171

172 **Discussion**

173 We conducted a systematic review and meta-analysis of 14 studies involving 2,568
174 individuals. This is the first systematic review on recurrent SARS-CoV-2 RNA positivity among
175 individuals who have recovered from COVID-19. The pooled estimate of the incidence of
176 recurrent SARS-CoV-2 positivity was 14.81%, confirming that recurrent positivity among
177 patients who have recovered and been discharged from hospital is relatively common. The
178 persistence of SARS-CoV-2 protein in some patients with recurrent SARS-CoV-2 positivity may

179 be a sign of active viral replication and so these patients could still be infectious, although the
180 level of infectiousness of individuals with recurrent positivity requires further evaluation. No
181 studies in this review provided evidence of new infections in the family members or close
182 contacts of the recovered patients that experienced recurrent positivity. Several studies clearly
183 reported that there was no new infection infected from the patients with recurrent positivity, the
184 study reported by Lan et al.[13] found that there we no family members infected. However, these
185 results do not rule out the possibility that individuals with repeat positivity may still be infectious
186 because most patients are likely to have strictly obeyed self-isolation protocols, as described by
187 Zheng et al.[14]

188 We estimated that the interval between the onset of the initial episode of the disease and
189 recurrent positivity was 35.44 days. The longest interval (50 days) was reported by Chen.[15]
190 The time from the last negative PCR test result (used as a discharge criterion) to recurrent
191 positivity was 9.76 days, with the longest interval (19 days) being reported by Huang.[16]
192 Regarding the incubation period, Jing et al.[17] reported that the estimated median of incubation
193 period was 8.13 days and the 99th percentile was 20.59 days. Considering these findings, a
194 treatment protocol for follow-up and observation of recovered patients, should be implemented.
195 Strict self-isolation and routine PCR retesting, where feasible, on days 9 to 20 after discharge
196 should be considered. Routine retesting should also be considered 35 to 50 days from the onset
197 of the illness. Further study should be conducted to elucidate whether prolonged persistent and
198 recurrent RNA positivity still potentially infectious.

199 Prolonged viral shedding could be considered as the underlying mechanism of recurrent
200 positivity as false-negative PCR test results have been reported.[18–22] The estimated duration
201 of viral shedding based on the absence of SARS-CoV-2 RNA detection was 20 days.[23]

202 However, the absence of nucleic acid alone cannot be used to determine whether viral shedding
203 occurred or potential infectiousness. Viral RNA could still be detected in a long time after the
204 disappearance of active virus,[24] and Yan et al.[25] categorized prolonged viral shedding with
205 the cut-off of 23 days.

206 Our review found that younger age, a longer length of stay during the initial illness, and
207 higher lymphocyte count was associated with an increased risk of recurrent positivity, while the
208 presence of diabetes mellitus, severe clinical disease were associated with a reduced risk. Several
209 studies have reported the determinants of prolonged viral shedding. A systematic review[26]
210 concluded that the use of corticosteroid was associated with delayed viral clearing. Another
211 review[27] reported that clearance of SARS-CoV-2 took longer in patients with gastrointestinal
212 disease than in those with respiratory disease, especially in children. A case series reported by
213 Huang et al. found that fecal specimens tended to have persistently detectable SARS-CoV-2 on
214 molecular tests for longer than other specimen types.[28] Another study[25] reported that in
215 adult patients, especially older patients had prolonged viral shedding, and that treatment with
216 lopinavir/ritonavir was associated with a shorter shedding period. Prolonged viral shedding has
217 also been reported to be associated with male sex, old age, concomitant hypertension, delayed
218 admission to hospital after illness onset, severe illness at admission, invasive mechanical
219 ventilation, and corticosteroid treatment.[29]

220 This review did not consider the underlying mechanism of the recurrent SARS-CoV-2
221 positivity; however, a previous non-systematic review[30] assessed possible mechanisms
222 underlying recurrent SARS-CoV-2 positivity and was unable to determine whether it was
223 attributable to false-negative results, reactivation, relapse or reinfection.

224 A study by Bao et al. give evidence that suggested that reinfection was unlikely. They
225 conducted trials on Rhesus macaques that were re-infected with SARS-CoV-2 on the early
226 recovery phase from initial infection characterized by weight loss, interstitial pneumonia, and
227 systemic viral dissemination mainly in respiratory and gastrointestinal tracts. The results showed
228 that primary SARS-CoV-2 infection protects from subsequent reinfection.[31] Wang et al. also
229 reported that there is no infectious risk of COVID-19 patients with long-term fecal SARS-CoV-2
230 RNA positivity, and that there were no abnormalities in the gastrointestinal examination of these
231 patients after they had been discharged.[32] However, a case report from Italy by Loconsole et
232 al. described a case of a 48-year-old man with re-detectable positive SARS-CoV-2 after two
233 consecutive negative SARS-CoV-2 molecular tests following his discharge from the hospital. A
234 month after home quarantine, the man developed new symptoms of dyspnea and chest pain,
235 causing him to re-admitted and his SARS-CoV-2 RNA test was positive on his readmission,[33]
236 making it necessary to consider reinfection or recurrence (relapse) as possible mechanisms for
237 recurrent SARS-CoV-2 RNA positivity on retesting. Further studies with larger sample sizes,
238 more longer follow-up, and more detailed measurements should be conducted to determine the
239 mechanisms underlying recurrent positivity.

240 Our meta-analysis produced large heterogeneity in some parameters reported; however,
241 a sub-group analysis and meta-regression could not be conducted to identify sources of between-
242 study heterogeneity in the pooled incidence estimates, because of insufficient study data. A
243 further review should be re-conducted once additional publications become available.

244

245 **Conclusion**

246 This systematic review provides evidence of SARS-CoV-2 recurrence of 14.81% among
247 COVID-19 patients. This review also provides pooled estimated time of onset to the re-
248 detectable positive duration was 35.44 days, and estimated time of the last negative to re-
249 detectable positive duration was 9.76 days. Patients with younger age, no history of diabetes,
250 mild and moderate severity, longer duration of onset to the last negative PCR, and higher
251 lymphocyte count are more likely to experience recurrent SARS-CoV-2 positivity. Strict self-
252 isolation for recovered patients should be well applied, and further studies should be conducted
253 to elucidate the possibility of infectious individuals with prolonged or recurrent RNA positivity.

254

255 **Abbreviations**

256 SARS-CoV-2: Severe acute respiratory syndrome-coronavirus-2; COVID-19: coronavirus
257 diseases-19; SMC: Semarang Medical Center; RNA: ribonucleic acid.

258

259 **Author contributions**

260 MA, AF, MR drafted the manuscript. All authors contributed to the development of selection
261 criteria, risk of a bias assessment strategy, and data extraction criteria. MA and AF developed the
262 search strategy, UB and RS provided statistical and methodological expertise. MR provided
263 expertise in COVID-19 from the perspective of pulmonary medicine. UB and SA contributed to
264 interpretation of the data. All authors read, provided feedback, and approved the final
265 manuscript.

266

267 **Funding**

268 This work was supported by the Ministry of Research and Technology/ National Research and
269 Innovation Agency, Republic of Indonesia (Grant no. 056/SP2H/LT/DRPM/2020). These
270 funding bodies had no role in the study design, data collection, data analysis, data interpretation,
271 or writing of the manuscript.

272

273 **Availability of data and materials**

274 All data generated or analyzed during this study are included in this published article or any
275 further information could be requested to the correspondent author.

276

277 **Ethics approval and consent to participate**

278 Systematic review protocol registered in PROSPERO under ID no. [CRD42020186306](#)

279 Table 1. Study characteristics included in the meta-analysis

Study	Published Date	City	Country	Peer-reviewed Published	Study design	Funding	Number of RP	Number of Population	Specimens of PCR retest	Onset to RP (days)	Negative to RP (days)
An [34]	30/03/2020	Shenzhen	China	No	Cohort	N/A	38	242	fecal and nasopharyngeal	N/A	Range: 5-7
Chen [15]	12/05/2020	Wuhan	China	No	Retrospective cohort	Guanggu Branch of Hubei Province Maternity and Childcare Hospital Fund Sanming Project of Medicine in Shenzhen Bill & Melinda Gates Foundations;	81	1067	oropharyngeal	Median: 50 IQR: 36.5-59.5	Median: 9 IQR: 7-10
Huang [16]	10/05/2020	Shenzhen	China	No	Cohort	National Natural Science Foundation of	69	414	nasopharyngeal	Median: 37 (N1 [*] =53) Median: 41 (N2 [*] =13) Median: 24 (N3 [*] =3)	Median: 19 Range: 6-52 (N=69)

Hui Zhu [35]	11/05/2020	Zhejiang	China	Yes	Retrospective cohort	China Ningbo HwaMei Key Research Fund and Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province	17	98	nasopharyngeal	Median: 21 IQR: 17-28 (Onset to negative)	Median: 4 IQR: 3-8.5
Jiang [10]	17/03/2020	Shangqiu	China	Yes	Crossectional	None	6	35	N/A	Median: 32.5 IQR: 31.25-36	Median: 10 IQR: 9.25-10
Li [12]	20/04/2020	Zhejiang	China	Yes	Cohort	Zhejiang University special scientific research fund for COVID- 19 prevention and control	6	13	sputum (oro- /naso- pharyngeal), fecal	Median: 32.5 IQR: 30.25- 39.25	Median: 10.5 IQR: 6.25-14
Ling [5]	05/05/2020	Shanghai	China	Yes	Retrospective cohort	First-class university and	11	66	fecal	N/A	N/A

						first-class discipline building project of the Fudan University and the Scientific research for special subjects on 2019- NCoV of the Shanghai Public Health Clinical Center National Key Research and Development Program of China						
Liu [11]	29/05/2020	Wuhan	China	Yes	Crossectional		11	150	oropharyngeal	Median: 38 IQR: 35-44	N/A	
Wong [36]	05/05/2020		Brunei	No	Crossectional	None	21	106	nasopharyngeal	Median: 32 IQR: 28.75- 33.5	Median: 14 IQR: 13.5-16	
Wu[37]	22/05/2020	Loudi	China	Yes	Crossectional	Grants No. 81902094 and	10	60	fecal and nasopharyngeal	Median: 21 IQR: 16.5-	Median: 11 IQR: 6.5-17	

						81600497 from the National Natural Science Foundation of China (Dr Zhou) and grant No. 2019RS1036 from the Science and Technology Plan Project of Hunan Province (Dr P.Wu).				22.75	
Xiao [6]	09/04/2020	Wuhan	China	Yes	Crossectional	None	15	70	oro- /naso-pharyngeal	N/A	N/A
Ye [38]	20/03/2020	Wuhan	China	Yes	Retrospective cohort	Medical Science Advancement Program (Clinical Medicine) of Wuhan University	5	55	oropharyngeal	N/A	Median: 9 IQR: 8-15
Yuan	08/04/2020	Shenzhen	China	Yes	Crossectional	Sanming Project of	25	172	fecal and	N/A	Mean:

[39]						Medicine in Shenzhen (SZSM201512005)			nasopharyngeal		5.23±4.13 (after discharge)
Zheng [14]	20/04/2020	Whenzou	China	Yes	Cohort	N/A	3	20	fecal and nasopharyngeal	N/A	7 (after discharge)

280 RP: recurrence positive PCR=rt-PCR: reverse transcription-polymerase chain reaction

281 Onset to negative and Negative to RP: negative determined as last (2nd) negative

282 Discharge from hospital, one day after 2nd negative

283 N1*, N12*, N3*: patients with 2,3,and 4 admission, respectively

284

285

286

287 **References**

288 1. WHO. Coronavirus disease (COVID-19) Situation Report – 144. 2020.

289 2. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of
290 coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. *J*
291 *Infect.* 2020;80:656–65.

292 3. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of
293 Coronavirus Disease 2019 in China. *N Engl J Med.* 2020;382:1708–20.

294 4. WHO. Clinical management of COVID-19. 2020.

295 5. Ling Y, Xu S-B, Lin Y-X, Tian D, Zhu Z-Q, Dai F-H, et al. Persistence and clearance of viral
296 RNA in 2019 novel coronavirus disease rehabilitation patients. *Chin Med J (Engl).*
297 2020;133:1039–43.

298 6. Xiao AT, Tong YX, Zhang S. False-negative of RT-PCR and prolonged nucleic acid
299 conversion in COVID-19: Rather than recurrence. *J. Med. Virol.* 2020.

300 7. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting
301 items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and
302 explanation. *BMJ.* England; 2015;350:g7647.

303 8. Azam M, Ratnawati M, Fibriana AI, Bahrudin U. Prevalence of positive SARS-CoV-2
304 recurrence in COVID-19 patients and its related characteristics: systematic review and meta-
305 analysis. [Internet]. PROSPERO 2020 CRD42020186306; 2020. Available from:
306 https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020186306

- 307 9. American National Institute of Health. Quality Assessment Tool for Observational Cohort and
308 Cross-Sectional Studies [Internet]. Available from: [https://www.nhlbi.nih.gov/health-](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools)
309 [topics/study-quality-assessment-tools](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools)
- 310 10. Jiang M, Li Y, Han M, Wang Z, Zhang Y, Du X. Recurrent PCR positivity after hospital
311 discharge of people with coronavirus disease 2019 (COVID-19). *J. Infect.* 2020.
- 312 11. Liu T, Wu S, Zeng G, Zhou F, Li Y, Guo F, et al. Recurrent positive SARS-CoV-2 - immune
313 certificate may not be valid. *J. Med. Virol. United States*; 2020.
- 314 12. Li Y, Hu Y, Yu Y, Zhang X, Li B, Wu J, et al. Positive result of Sars-Cov-2 in faeces and
315 sputum from discharged patient with COVID-19 in Yiwu, China. *J Med Virol. United States*;
316 2020;
- 317 13. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR Test Results in Patients
318 Recovered from COVID-19. *JAMA - J Am Med Assoc.* 2020;323:1502–3.
- 319 14. Zheng KI, Wang X-B, Jin X-H, Liu W-Y, Gao F, Chen Y-P, et al. A Case Series of
320 Recurrent Viral RNA Positivity in Recovered COVID-19 Chinese Patients. *J. Gen. Intern. Med.*
321 2020. p. 1–2.
- 322 15. Chen J, Xu X, Hu J, Chen Q, Xu F, Liang H, et al. Clinical Course and Risk Factors for
323 Recurrence of Positive SARS-CoV-2 RNA: A Retrospective Cohort Study from Wuhan, China.
324 *medRxiv [Internet]*. 2020;2020.05.08.20095018. Available from:
325 <http://medrxiv.org/content/early/2020/05/12/2020.05.08.20095018.abstract>
- 326 16. Huang J, Zheng L, Li Z, Hao S, Ye F, Chen J, et al. Recurrence of SARS-CoV-2 PCR
327 positivity in COVID-19 patients: a single center experience and potential implications. *medRxiv*

- 328 [Internet]. 2020;2020.05.06.20089573. Available from:
329 <http://medrxiv.org/content/early/2020/05/10/2020.05.06.20089573.abstract>
- 330 17. Jing Q, You C, Lin Q, Hu T, Yu S, Zhou X-H. Estimation of incubation period distribution
331 of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up
332 study. medRxiv [Internet]. 2020;2020.03.06.20032417. Available from:
333 <http://medrxiv.org/content/early/2020/03/10/2020.03.06.20032417.abstract>
- 334 18. Chen Z, Li Y, Wu B, Hou Y, Bao J, Deng X. A Patient with COVID-19 Presenting a False-
335 Negative Reverse Transcriptase Polymerase Chain Reaction Result. Korean J Radiol [Internet].
336 The Korean Society of Radiology; 2020;21:623–4. Available from:
337 <https://doi.org/10.3348/kjr.2020.0195>
- 338 19. Li D, Wang D, Dong J, Wang N, Huang H, Xu H, et al. False-Negative Results of Real-Time
339 Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome
340 Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases.
341 Korean J. Radiol. 2020. p. 505–8.
- 342 20. Xie C, Lu J, Wu D, Zhang L, Zhao H, Rao B, et al. False negative rate of COVID-19 is
343 eliminated by using nasal swab test. Travel Med. Infect. Dis. 2020. p. 101668.
- 344 21. West CP, Montori VM, Sampathkumar P. COVID-19 Testing: The Threat of False-Negative
345 Results. Mayo Clin Proc. 2020;95:1127–9.
- 346 22. Feng H, Liu Y, Lv M, Zhong J. A case report of COVID-19 with false negative RT-PCR test:
347 necessity of chest CT. Jpn J Radiol. 2020;38:409–10.
- 348 23. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality

- 349 of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*
350 (London, England). 2020;395:1054–62.
- 351 24. Lin W-HW, Kouyos RD, Adams RJ, Grenfell BT, Griffin DE. Prolonged persistence of
352 measles virus RNA is characteristic of primary infection dynamics. *Proc Natl Acad Sci U S A*.
353 2012;109:14989–94.
- 354 25. Yan D, Liu X-Y, Zhu Y-N, Huang L, Dan B-T, Zhang G-J, et al. Factors associated with
355 prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-
356 critically ill patients with SARS-CoV-2 infection. *Eur Respir J*. 2020;
- 357 26. Li H, Chen C, Hu F, Wang J, Zhao Q, Gale RP, et al. Impact of corticosteroid therapy on
358 outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic
359 review and meta-analysis. *Leukemia*. 2020;34:1503–11.
- 360 27. Xing YH, Ni W, Wu Q, Li WJ, Li GJ, Wang W Di, et al. Prolonged viral shedding in feces
361 of pediatric patients with coronavirus disease 2019. *J Microbiol Immunol Infect*. 2020;53:473–
362 80.
- 363 28. Huang J, Mao T, Li S, Wu L, Xu X, Li H, et al. Long period dynamics of viral load and
364 antibodies for SARS-CoV-2 infection: an observational cohort study. *medRxiv [Internet]*.
365 2020;2020.04.22.20071258. Available from:
366 <http://medrxiv.org/content/early/2020/04/27/2020.04.22.20071258.abstract>
- 367 29. Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, et al. Factors Associated With Prolonged Viral
368 RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19). *Clin Infect Dis*
369 [Internet]. 2020; Available from: <https://doi.org/10.1093/cid/ciaa351>

- 370 30. Kang H, Wang Y, Tong Z, Liu X. Retest positive for SARS-CoV-2 RNA of “recovered”
371 patients with COVID-19: Persistence, sampling issues, or re-infection? *J Med Virol*. 2020;
- 372 31. Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Lack of Reinfection in Rhesus Macaques
373 Infected with SARS-CoV-2. *bioRxiv* [Internet]. 2020;2020.03.13.990226. Available from:
374 <http://biorxiv.org/content/early/2020/05/01/2020.03.13.990226.abstract>
- 375 32. Wang Q-X, Huang K-C, Qi L, Zeng X-H, Zheng S-L. No infectious risk of COVID-19
376 patients with long-term fecal 2019-nCoV nucleic acid positive. *Eur Rev Med Pharmacol Sci*.
377 *Italy*; 2020;24:5772–7.
- 378 33. Loconsole D, Passerini F, Palmieri VO, Centrone F, Sallustio A, Pugliese S, et al.
379 Recurrence of COVID-19 after recovery: a case report from Italy. *Infection*. 2020. p. 1–3.
- 380 34. An J, Liao X, Xiao T, Qian S, Yuan J, Ye H, et al. Clinical characteristics of the recovered
381 COVID-19 patients with re-detectable positive RNA test. *medRxiv* [Internet].
382 2020;2020.03.26.20044222. Available from:
383 <http://medrxiv.org/content/early/2020/03/30/2020.03.26.20044222.abstract>
- 384 35. Zhu H, Fu L, Jin Y, Shao J, Zhang S, Zheng N, et al. Clinical features of COVID-19
385 convalescent patients with re- positive nucleic acid detection. *J Clin Lab Anal*. 2020;00:e23392.
- 386 36. Wong J, Koh WC, Momin RN, Alikhan MF, Fadillah N, Naing L. Probable causes and risk
387 factors for positive SARS-CoV-2 test in recovered patients: Evidence from Brunei Darussalam.
388 *medRxiv* [Internet]. 2020;2020.04.30.20086082. Available from:
389 <http://medrxiv.org/content/early/2020/05/05/2020.04.30.20086082.abstract>
- 390 37. Wu J, Liu X, Liu J, Liao H, Long S, Zhou N, et al. Coronavirus Disease 2019 Test Results

391 After Clinical Recovery and Hospital Discharge Among Patients in China. JAMA Netw open.
392 2020;3:e209759.

393 38. Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. Clinical characteristics of severe acute
394 respiratory syndrome coronavirus 2 reactivation. J Infect. 2020;80:e14–7.

395 39. Yuan J, Kou S, Liang Y, Zeng J, Pan Y, Liu L. PCR Assays Turned Positive in 25
396 Discharged COVID-19 Patients. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2020;

397

398

399

400

401 397 records identified through database searching
402 (Pubmed, MedRxiv, BioRxiv, Cochrane Library,
403 ClinicalTrial.Gov, WHO clinical trial registry)

0 records identified through other sources

404

405

406

407

408

409

392 records after duplicates removal
& being screened

411

412 371 records excluded, articles didn't report
413 positive SARS-CoV-2 recurrence

414 21 full texts assessed for eligibility

415

416

1 rapid review article excluded
6 case report articles excluded

417

14 studies included in meta-analysis


418

419

420 **Figure 1. PRISMA-P study selection diagram**

421

422




423

424 **Figure 2. A meta-analysis of the pooled estimated incidence of SARS-CoV-2 RNA positivity**

425


426



427
 428 **Figure 3. A meta-analysis of the pooled estimated onset to recurrent SARS-CoV-2 RNA**
 429 **positivity (days)**

430


431




432
 433 **Figure 4. A meta-analysis of the pooled estimated last negative to recurrent SARS-CoV-2**
 434 **RNA positivity (days)**

435


436




437



438




439




440




441



442






443



444





448 **Figure 5. A meta-analysis of the pooled estimated RR of characteristics and clinical**
 449 **features to recurrent SARS-CoV-2 RNA positivity**

450